Hatef Massoumi

No disrespect toward everyone else’s excitement about THR-beta & GLP-1 agonists, but my diagnostic/therapeutic award of 2024 goes to PeTH. You are the best!

I think paying attention to the patient’s whole clinical picture is the key. Criteria tend to ignore some important factors such as nutritional status, size of the liver, age, presence or absence of ascites, and even how patients feel after receiving steroid.

Things We Do for No Reason™: Avoiding naltrexone for alcohol use disorder in liver disease Hospitalizations related to alcohol use disorder (AUD) are common. Yet, few patients receive pharmacotherapy consistent with guideline recommendations. Previous concerns over the potential hepatotoxi...

Great summary of evidence for safety of naltrexone in liver disease 👇

To all incoming GI fellows
Congratulations!!
Make sure you get the best out of the 3 yrs of training no matter where you end up. Make yourself as exposed as safely as possible to as many academic, clinical and social scenarios. Future is yours but you have to grab it. Trust me!

AKI can be the downside of “as-needed blood pressure medication”, especially when we use IV drugs.
Thank you @ebtapper.bsky.social for sharing.

I have always thought that the intestinal surface and its lymphatics are the main source of fluid leak and that’s why patients with short gut/TPN related liver disease don’t develop much ascites. What am I missing?

Please add me to the list
Thx